Database : MEDLINE
Search on : Iodine and Radioisotopes [Words]
References found : 46286 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 4629 go to page                         

  1 / 46286 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29489641
[Au] Autor:Yoo RE; Kim JH; Paeng JC; Park YJ
[Ad] Address:Department of Radiology, Seoul National University College of Medicine, Seoul, Korea.
[Ti] Title:Radiofrequency ablation for treatment of locally recurrent thyroid cancer presenting as a metastatic lymph node with dense macrocalcification: A case report and literature review.
[So] Source:Medicine (Baltimore);97(9):e0003, 2018 Mar.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Long-term recurrence rate of differentiated thyroid carcinoma has been reported to be as high as 30%. Repeat surgery may be challenging due to normal tissue plane distortion secondary to postoperative fibrosis, especially for small-sized recurrences. Recently, radiofrequency ablation (RFA) has been suggested to be a safe and effective alternative for high-risk patients or those who refuse surgery. Nonetheless, the efficacy of RFA remains questionable for densely calcified lymph nodes, which would have an increased likelihood of leaving residues after RFA. PATIENT CONCERNS: We present a case of a successful combined treatment of a metastatic lymph node with dense macrocalcification with the use of a single RFA session and radioactive iodine (RAI) ablation in a patient with a previous history of total thyroidectomy and neck node dissection for papillary thyroid carcinoma. DIAGNOSES: A 71-year-old man with papillary thyroid carcinoma underwent total thyroidectomy and neck node dissection followed by RAI ablation. The stimulated serum thyroglobulin level was 4.74 ng/mL at the time of RAI ablation, and the follow-up ultrasonography 3 months later revealed a 15-mm lymph node with dense macrocalcification at the right cervical level III. INTERVENTIONS: After confirming metastasis on cytology, the lesion was treated with ultrasound-guided RFA. OUTCOMES: The single RFA session combined with RAI ablation led to biochemical remission at 5 months after RFA, and complete resolution of structural recurrence including macrocalcification was observed 7 months after the second RAI (1 year after RFA). The patient remained free of recurrence at the 5-year follow-up. LESSONS: RFA may offer a safe and effective alternative to 'berry picking' surgery in cases of surgical ineligibility or patient refusal of surgery even when the target lesions contain dense macrocalcification.
[Mh] MeSH terms primary: Carcinoma, Papillary/pathology
Carcinoma, Papillary/surgery
Catheter Ablation
Neoplasm Recurrence, Local/pathology
Neoplasm Recurrence, Local/surgery
Thyroid Neoplasms/pathology
Thyroid Neoplasms/surgery
[Mh] MeSH terms secundary: Aged
Calcinosis/pathology
Carcinoma, Papillary/diagnostic imaging
Humans
Iodine Radioisotopes/therapeutic use
Lymph Nodes/diagnostic imaging
Lymph Nodes/pathology
Lymphatic Metastasis
Male
Neoplasm Recurrence, Local/diagnostic imaging
Retrospective Studies
Thyroid Neoplasms/diagnostic imaging
Thyroidectomy
Ultrasonography
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Iodine Radioisotopes)
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180301
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000010003

  2 / 46286 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29465605
[Au] Autor:Wang R; Zhou K; Fan Q; Chen H; Fan C
[Ad] Address:Department of Nuclear Medicine, West China Hospital of Sichuan University, Guoxue Alley, Chengdu, Sichuan, People's Republic of China.
[Ti] Title:A false-positive I-131 finding of duodenum diverticulum in thyroid cancer evaluation by SPECT/CT: A case report.
[So] Source:Medicine (Baltimore);97(8):e9997, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Iodine-131 (I-131) is a sensitive marker for the detection of differentiated thyroid cancer (DTC). I-131 whole-body scintigraphy (WBS) has been used widely in evaluation of DTC patient. However, I-131 WBS exists many false-positive uptake of I-131 because radioiodine uptake can also be seen in healthy tissue or in a variety of benign and malignant non-thyroidal tumors. PATIENT CONCERNS: A 44-year-old woman with a papillary thyroid carcinoma for the purpose of ablation therapy after a total thyroidectomy. I-131 WBS showed intensive uptake by thyroid remnant. Meanwhile, a focus of increased activity was seen in right upper abdomen. DISGNOSES, INTERVENTIONS AND OUTCOMES: Based on an I-131 single-photon emission computed tomography/computed tomography (SPECT/CT) fusion imaging combining a Tc-99m pertechnetate dynamic SPECT scan and SPECT/CT fusion imaging with oral administration of iodine contrast agent, a descending duodenum diverticulum was diagnosed. This patient was then treated with conservative treatment, such as diet regulation, rest, appropriate use of antacids and antispasmodic agents, etc. So far, she recovered uneventfully with no any complications. LESSONS: Duodenum diverticulum is a rare false-positive uptake of I-131, it might be a diagnostic challenge when there are many false-positive uptake of I-131 in evaluation of DTC. So it must be significant to be familiar with these physiologic and pathologic variants of I-131 uptake and make further efforts to accurately interpret radioiodine scintigraphy results.
[Mh] MeSH terms primary: Diverticulum/diagnostic imaging
Duodenal Diseases/diagnostic imaging
Iodine Radioisotopes
Single Photon Emission Computed Tomography Computed Tomography
Thyroid Neoplasms/diagnostic imaging
[Mh] MeSH terms secundary: Adult
Carcinoma, Papillary
Diverticulum/etiology
Duodenal Diseases/etiology
False Positive Reactions
Female
Humans
Single Photon Emission Computed Tomography Computed Tomography/methods
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Iodine Radioisotopes); 0 (Iodine-131)
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009997

  3 / 46286 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29303890
[Au] Autor:Danish H; Ferris MJ; Balagamwala E; Switchenko JM; Patel KR; Choudhary M; Craven C; Mendoza P; Suh J; Bergstrom C; Grossniklaus HE; M Aaberg T; Singh A; Crocker IR; Khan MK
[Ad] Address:Department of Radiation Oncology.
[Ti] Title:Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma.
[So] Source:Melanoma Res;28(2):120-125, 2018 Apr.
[Is] ISSN:1473-5636
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:For the treatment of choroidal melanoma, palladium-103 (Pd) and ruthenium-106 (Ru) plaque brachytherapy shows reduced toxicity compared with the historical standard iodine-125. No report has directly compared the clinical outcomes between Pd and Ru, and the reasons for the selection of one over the other remain purely theoretical. Patients with choroidal melanoma with apical tumor height up to 5 mm were included. Patients from Emory University were treated with Pd between 1993 and 2012. Patients from Cleveland Clinic were treated with Ru between 2005 and 2010. Medical records were retrospectively reviewed. We compared post-treatment visual acuity (VA), toxicity, and oncologic outcomes. Pd patients (n=124) and Ru patients (n=42) had a median follow-up of 4.2 and 5.0 years, respectively. Radiation retinopathy-free survival was similar for both radioisotopes, but Ru had lower grades of retinopathy (P=0.006). Pd was associated with worse VA preservation (≥20/40) by year 3 (odds ratio: 3.8; 95% confidence interval: 1.01-14.31, P=0.048). Pd was associated with higher distant metastases-free survival (DMFS) in multivariate analysis (hazard ratio: 0.10; 95% confidence interval: 0.02-0.38; P<0.001). Ru had lower grades of radiation retinopathy and improved long-term VA preservation, but also inferior DMFS, compared with Pd. Because of the inherent limitations of a retrospective analysis, the significance of the inferior DMFS for Ru remains unclear, although the suggestion of a slight inferiority in terms of DMFS for Ru is consistent with the other limited literature. On the basis of this study, we believe that both radioisotopes remain appropriate for the treatment of small choroidal melanomas up to 5 mm in apical height.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[St] Status:In-Data-Review
[do] DOI:10.1097/CMR.0000000000000420

  4 / 46286 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29485411
[Au] Autor:Pak K; Shin S; Kim SJ; Kim IJ; Chang S; Koo P; Kwak J; Kim JH
[Ti] Title:Response of Retinoic Acid in Patients with Radioactive Iodine-Refractory Thyroid Cancer: A Meta-Analysis.
[So] Source:Oncol Res Treat;41(3):100-104, 2018.
[Is] ISSN:2296-5262
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:PURPOSE: The purpose of this study was to evaluate the response of retinoic acid (RA) in radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). METHODS: Systematic searches of MEDLINE (from inception to December 2016) and of EMBASE (from inception to December 2016) were performed for English-language publications on thyroid cancer treated with RA. Studies were classified according to the response criteria used: (1) 123I or 131I whole body scintigraphy (WBS), (2) serum thyroglobulin (Tg) level, (3) the response evaluation criteria in solid tumors (RECIST) version 1.0, and (4) World Health Organization (WHO) criteria. RESULTS: Disease response rates as determined by WBS ranged widely between 6.2% and 46.1% with a pooled disease response rate of 27.6% (95% confidence interval: 21.7-34.0%). Response rates as determined by Tg level ranged from 56.6% to 83.3% (pooled response rate 61.3% (51.0-70.9%)), RECIST response rates from 0% to 45.5% (pooled response rate 17.0% (1.4-44.5%)), and according to WHO criteria, the pooled response rate was 30.8% (12.7-52.7%). CONCLUSIONS: A minority of patients with RAI-refractory DTC respond to RA treatment.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[St] Status:In-Process
[do] DOI:10.1159/000484206

  5 / 46286 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29177260
[Au] Autor:Tay WL; Tong AKT; Hui KYD; Tang YLC; Chng CL
[Ad] Address:Department of Endocrinology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore. weilin.tay@mohh.com.sg.
[Ti] Title:Radioiodine associated de novo Graves' opthalmopathy in an Asian cohort.
[So] Source:Hell J Nucl Med;20(3):227-231, 2017 Sep-Dec.
[Is] ISSN:1790-5427
[Cp] Country of publication:Greece
[La] Language:eng
[Ab] Abstract:Radioactive iodine in the treatment of Graves' disease has been associated with the development of de novo Graves' ophthalmopathy (GO). In this report, we describe five individuals who required extensive ophthalmic treatment for post-RAI de novo GO.
[Mh] MeSH terms primary: Graves Disease/radiotherapy
Graves Ophthalmopathy/diet therapy
Graves Ophthalmopathy/etiology
Iodine Radioisotopes/adverse effects
Iodine Radioisotopes/therapeutic use
Radiation Injuries/diagnostic imaging
Radiation Injuries/etiology
[Mh] MeSH terms secundary: Adult
Diagnosis, Differential
Female
Graves Disease/diagnostic imaging
Humans
Male
Middle Aged
Radiation Injuries/prevention & control
Radiopharmaceuticals/adverse effects
Radiopharmaceuticals/therapeutic use
Singapore
Young Adult
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Iodine Radioisotopes); 0 (Radiopharmaceuticals)
[Em] Entry month:1802
[Cu] Class update date: 180223
[Lr] Last revision date:180223
[Js] Journal subset:IM
[Da] Date of entry for processing:171128
[St] Status:MEDLINE
[do] DOI:10.1967/s002449910606

  6 / 46286 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29177256
[Au] Autor:Chen Y; Huang J; Wang Y; Xie S; He F
[Ad] Address:Nuclear medicine department of Quanzhou, East Road 248#, Licheng District, Quanzhou City, China, 362000. 1526797743@qq.com.
[Ti] Title:Errors in the absorbed and the administered I therapeutic dose in patients with Graves' disease. A suggested more precise technique.
[So] Source:Hell J Nucl Med;20(3):217-221, 2017 Sep-Dec.
[Is] ISSN:1790-5427
[Cp] Country of publication:Greece
[La] Language:eng
[Ab] Abstract:OBJECTIVE: The aim of this study was to evaluate the relative error (RE) in the thyroid absorbed dose (TD) of iodine-131 ( I) in patients with Graves' disease comparing the simplified Quimby-Marinelli-Hine formula method (sQMHF) and the Standard Operational Procedures for dosimetry (SOPD) recommended by the European Association of Nuclear Medicine. PATIENTS AND METHODS: This study included 45 patients with Graves' disease 12 men and 33 women; age 44.1±12.8 years. Thyroid mass (TM) was measured using ultrasound. Uptake of I (RAIU) was tested at 2, 4-6, 24, 48-72, and 96-168h after its administration and the half-life (T ) and resident time (RT) of I were computed. According to the sQMHF, a prescribed TD of 75Gy required 3.7MBq/g of I, correction based on the RAIU and T . Subsequently, the therapeutic TD was computed according to the SOPD and the RE was recorded. The data were analyzed using t-tests. RESULTS: The TM, RAIU , therapeutic TD, and RE were 36.5±23.9g, 0.54±0.14, 89.4±9.4Gy, and -0.01±0.02, respectively. There was a significant difference (t-value 9.84, P<0.01) between the prescribed and therapeutic TD because the sQMHF ignores the absorbed dose deposited in the thyroid during the first 24h, which is included in the SOPD. In addition, the RE was significantly smaller than the variable coefficient (VC) of the therapeutic TD (t=-39.6, P<0.01). CONCLUSION: When the activity of I was calculated using the simplified Q-M-H formula, the therapeutic absorbed thyroid dose was significantly higher than what was expected for the prescribed dose. Precision of the individualized therapeutic absorbed dose could be improved by computing the activity of I using the standard operational procedures for dosimetry of the EANM.
[Mh] MeSH terms primary: Absorption, Physicochemical
Drug Administration Schedule
Graves Disease/metabolism
Graves Disease/radiotherapy
Iodine Radioisotopes/administration & dosage
Iodine Radioisotopes/pharmacokinetics
Medication Errors/prevention & control
[Mh] MeSH terms secundary: Adult
Female
Humans
Male
Metabolic Clearance Rate
Radiopharmaceuticals/administration & dosage
Radiopharmaceuticals/pharmacokinetics
Radiotherapy Dosage
Retrospective Studies
Treatment Outcome
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Iodine Radioisotopes); 0 (Iodine-131); 0 (Radiopharmaceuticals)
[Em] Entry month:1802
[Cu] Class update date: 180223
[Lr] Last revision date:180223
[Js] Journal subset:IM
[Da] Date of entry for processing:171128
[St] Status:MEDLINE
[do] DOI:10.1967/s002449910602

  7 / 46286 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27774839
[Au] Autor:Jeong HS; Choi EK; Song IU; Chung YA; Park JS; Oh JK
[Ad] Address:1 Department of Radiology, Incheon St. Mary's Hospital, The Catholic University of Korea , Incheon, South Korea .
[Ti] Title:Differences in Brain Glucose Metabolism During Preparation for I Ablation in Thyroid Cancer Patients: Thyroid Hormone Withdrawal Versus Recombinant Human Thyrotropin.
[So] Source:Thyroid;27(1):23-28, 2017 Jan.
[Is] ISSN:1557-9077
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: In preparation for I ablation, temporary withdrawal of thyroid hormone is commonly used in patients with thyroid cancer after total thyroidectomy. The current study aimed to investigate brain glucose metabolism and its relationships with mood or cognitive function in these patients using F-fluoro-2-deoxyglucose positron emission tomography ( F-FDG-PET). METHOD: A total of 40 consecutive adult patients with thyroid carcinoma who had undergone total thyroidectomy were recruited for this cross-sectional study. At the time of assessment, 20 patients were hypothyroid after two weeks of thyroid hormone withdrawal, while 20 received thyroid hormone replacement therapy and were euthyroid. All participants underwent brain F-FDG-PET scans and completed mood questionnaires and cognitive tests. Multivariate spatial covariance analysis and univariate voxel-wise analysis were applied for the image data. RESULTS: The hypothyroid patients were more anxious and depressed than the euthyroid participants. The multivariate covariance analysis showed increases in glucose metabolism primarily in the bilateral insula and surrounding areas and concomitant decreases in the parieto-occipital regions in the hypothyroid group. The level of thyrotropin was positively associated with the individual expression of the covariance pattern. The decreased F-FDG uptake in the right cuneus cluster from the univariate analysis was correlated with the increased thyrotropin level and greater depressive symptoms in the hypothyroid group. CONCLUSIONS: These results suggest that temporary hypothyroidism, even for a short period, may induce impairment in glucose metabolism and related affective symptoms.
[Mh] MeSH terms primary: Brain/metabolism
Glucose/metabolism
Thyroid Neoplasms/metabolism
[Mh] MeSH terms secundary: Adult
Affect/physiology
Anxiety/diagnostic imaging
Anxiety/metabolism
Anxiety/psychology
Brain/diagnostic imaging
Cognition/physiology
Cross-Sectional Studies
Depression/diagnostic imaging
Depression/metabolism
Depression/psychology
Female
Fluorodeoxyglucose F18
Humans
Iodine Radioisotopes/therapeutic use
Male
Middle Aged
Positron-Emission Tomography
Thyroid Neoplasms/diagnostic imaging
Thyroid Neoplasms/psychology
Thyroid Neoplasms/radiotherapy
Thyroidectomy
Thyrotropin/blood
Thyroxine/blood
Triiodothyronine/blood
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Iodine Radioisotopes); 06LU7C9H1V (Triiodothyronine); 0Z5B2CJX4D (Fluorodeoxyglucose F18); 9002-71-5 (Thyrotropin); IY9XDZ35W2 (Glucose); Q51BO43MG4 (Thyroxine)
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[Js] Journal subset:IM
[Da] Date of entry for processing:161025
[St] Status:MEDLINE
[do] DOI:10.1089/thy.2016.0293

  8 / 46286 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29437784
[Au] Autor:De la Vieja A; Santisteban P
[Ad] Address:Tumor Endocrine UnitChronic Disease Program (UFIEC), Instituto de Salud Carlos III, Madrid, Spain adelavieja@isciii.es.
[Ti] Title:Role of iodide metabolism in physiology and cancer.
[So] Source:Endocr Relat Cancer;25(4):R225-R245, 2018 Apr.
[Is] ISSN:1479-6821
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Iodide (I ) metabolism is crucial for the synthesis of thyroid hormones (THs) in the thyroid and the subsequent action of these hormones in the organism. I is principally transported by the sodium iodide symporter (NIS) and by the anion exchanger PENDRIN, and recent studies have demonstrated the direct participation of new transporters including anoctamin 1 (ANO1), cystic fibrosis transmembrane conductance regulator (CFTR) and sodium multivitamin transporter (SMVT). Several of these transporters have been found expressed in various tissues, implicating them in I recycling. New research supports the exciting idea that I participates as a protective antioxidant and can be oxidized to hypoiodite, a potent oxidant involved in the host defense against microorganisms. This was possibly the original role of I in biological systems, before the appearance of TH in evolution. I per se participates in its own regulation, and new evidence indicates that it may be antineoplastic, anti-proliferative and cytotoxic in human cancer. Alterations in the expression of I transporters are associated with tumor development in a cancer-type-dependent manner and, accordingly, NIS, CFTR and ANO1 have been proposed as tumor markers. Radioactive iodide has been the mainstay adjuvant treatment for thyroid cancer for the last seven decades by virtue of its active transport by NIS. The rapid advancement of techniques that detect radioisotopes, in particular I , has made NIS a preferred target-specific theranostic agent.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:In-Data-Review
[do] DOI:10.1530/ERC-17-0515

  9 / 46286 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29384971
[Au] Autor:Lv WF; Lu D; Xiao JK; Mukhiya G; Tan ZX; Cheng DL; Zhou CZ; Zhang XM; Zhang ZF; Hou CL
[Ad] Address:Department of Interventional Radiology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.
[Ti] Title:The side effects and complications of percutaneous iodine-125 seeds implantation under CT-guide for patients with advanced pancreatic cancer.
[So] Source:Medicine (Baltimore);96(52):e9535, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: The present study investigates the side effects and complications of computed tomography (CT)-guided percutaneous iodine-125 (I-125) seeds implantation for advanced pancreatic cancer. METHODS: The clinical data were retrospectively analyzed for patients treated with implantation of I-125 seeds under CT-guide in our hospital from May 2010 to April 2015. The side effects and complications were collected and their possible reasons were analyzed. RESULTS: A total of 78 patients were enrolled. The side effects were categorized as fever in 29 cases (37.18%), abdominal pain in 26 cases (33.33%), nausea and vomiting in 9 cases (11.54%), diarrhea in 5 cases (6.41%), and constipation in 4 cases (5.13%). Complications were composed of pancreatitis in 9 cases (11.54%), infection in 5 cases (6.41%), seed migration in 2 cases (2.56%), intestinal perforation in 1 case (1.28%), and intestinal obstruction in 1 case. The incidence of complication was 23.08% (18/78). The difference in incidence of complication was statistically significant between patients implanted with ≤27 seeds and those with >27 seeds (P = .032). CONCLUSION: The side effects and complications frequently occur in implantation of I-125 seeds for patients with advanced pancreatic cancer. More concern should be given to the patients treated by this technique.
[Mh] MeSH terms primary: Brachytherapy/adverse effects
Brachytherapy/methods
Iodine Radioisotopes/therapeutic use
Pancreatic Neoplasms/radiotherapy
[Mh] MeSH terms secundary: Adult
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Radiography, Interventional
Retrospective Studies
Tomography, X-Ray Computed
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Iodine Radioisotopes); 0 (Iodine-125)
[Em] Entry month:1802
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009535

  10 / 46286 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29331558
[Au] Autor:Bautista AT; Miyake Y; Matsuzaki H; Iizuka Y; Horiuchi K
[Ad] Address:Philippine Nuclear Research Institute - Department of Science and Technology (PNRI-DOST), Commonwealth Ave., Diliman, Quezon City 1101, Philippines; Department of Nuclear Engineering and Management, The University of Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan. Electronic address: atbautistavii@pnri.dos
[Ti] Title:High-resolution I bomb peak profile in an ice core from SE-Dome site, Greenland.
[So] Source:J Environ Radioact;184-185:14-21, 2018 Apr.
[Is] ISSN:1879-1700
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:I in natural archives, such as ice cores, can be used as a proxy for human nuclear activities, age marker, and environmental tracer. Currently, there is only one published record of I in ice core (i.e., from Fiescherhorn Glacier, Swiss Alps) and its limited time resolution (1-2 years) prevents the full use of I for the mentioned applications. Here we show I concentrations in an ice core from SE-Dome, Greenland, covering years 1956-1976 at a time resolution of ∼6 months, the most detailed record to date. Results revealed I bomb peaks in years 1959, 1962, and 1963, associated to tests performed by the former Soviet Union, one year prior, in its Novaya Zemlya test site. All I bomb peaks were observed in winter (1958.9, 1962.1, and 1963.0), while tritium bomb peaks, another prominent radionuclide associated with nuclear bomb testing, were observed in spring or summer (1959.3, and 1963.6; Iizuka et al., 2017). These results indicate that I bomb peaks can be used as annual and seasonal age markers for these years. Furthermore, we found that I recorded nuclear fuel reprocessing signals and that these can be potentially used to correct timing of estimated I releases during years 1964-1976. Comparisons with other published records of I in natural archives showed that I can be used as common age marker and tracer for different types of records. Most notably, the 1963 I bomb peak can be used as common age marker for ice and coral cores, providing the means to reconcile age models and associated trends from the polar and tropical regions, respectively.
[Mh] MeSH terms primary: Ice Cover/chemistry
Iodine Radioisotopes/analysis
Nuclear Weapons
Radiation Monitoring
Radioactive Pollutants/analysis
[Mh] MeSH terms secundary: Greenland
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Iodine Radioisotopes); 0 (Radioactive Pollutants)
[Em] Entry month:1802
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[Js] Journal subset:IM
[Da] Date of entry for processing:180115
[St] Status:MEDLINE


page 1 of 4629 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information